Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
18.64
+0.19 (1.03%)
At close: Nov 4, 2024, 4:00 PM
18.69
+0.05 (0.27%)
After-hours: Nov 4, 2024, 7:29 PM EST
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 37,851 employees as of December 31, 2023. The number of employees increased by 1,025 or 2.78% compared to the previous year.
Employees
37,851
Change (1Y)
1,025
Growth (1Y)
2.78%
Revenue / Employee
$430,372
Profits / Employee
-$11,968
Market Cap
21.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Labcorp Holdings | 67,000 |
Baxter International | 60,000 |
ICON Public Limited Company | 41,100 |
STERIS | 18,179 |
Zimmer Biomet Holdings | 18,000 |
Molina Healthcare | 18,000 |
The Cooper Companies | 15,000 |
BeiGene | 10,600 |
TEVA News
- 3 days ago - Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition - GlobeNewsWire
- 3 days ago - Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) - GlobeNewsWire
- 4 days ago - Teva Fined Around $500 Million Over MS Drug Competition Concerns - WSJ
- 4 days ago - Teva Statement on European Commission Decision; Company to Appeal - GlobeNewsWire
- 4 days ago - Teva fined $503 mln by EU for disparaging rival product - Reuters
- 12 days ago - Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt - Seeking Alpha
- 13 days ago - Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - GlobeNewsWire
- 14 days ago - 3 Attractive Biotechs With Recent Positives - Seeking Alpha